Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Fromm

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Cancer Biology & Therapy|February 16, 2024
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cellsHongjie Wang, Theo Koob, Jonathan R Fromm, et al.
American Journal of Clinical Pathology|June 27, 2021
De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine LearningPaul D Simonson, Yue Wu, David Wu, et al.
Clinical Neuropathology|October 11, 2017
The first report of human primary thoracic spine mast cell sarcoma: a case reportAli C Ravanpay, Jonathan R Fromm, Kerstin L Edlefsen, et al.
Cytometry. Part B, Clinical Cytometry|August 6, 2014
Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemiaLorinda Soma, David Wu, Xueyan Chen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2014
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencingStephen J Salipante, Jonathan R Fromm, Jay Shendure, et al.
Cytometry. Part B, Clinical Cytometry|July 22, 2014
Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemiaLorinda Soma, David Wu, Xueyan Chen, et al.
Cytometry. Part B, Clinical Cytometry|September 7, 2016
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapySindhu Cherian, Valerie Miller, Vivian McCullouch, et al.
Cytometry. Part B, Clinical Cytometry|November 4, 2015
Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosisSindhu Cherian, Vivian McCullouch, Valerie Miller, et al.
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Case study interpretation: Report from the ICCS Annual Meeting, Seattle, 2014Jonathan R Fromm, Damian J Tagliente, Aaron C Shaver, et al.
American Journal of Clinical Pathology|September 17, 2024
Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistryXueyan Chen, Lori Soma, Claire Murphy, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Cancer Biology & Therapy|February 16, 2024
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cellsHongjie Wang, Theo Koob, Jonathan R Fromm, et al.
American Journal of Clinical Pathology|June 27, 2021
De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine LearningPaul D Simonson, Yue Wu, David Wu, et al.
Clinical Neuropathology|October 11, 2017
The first report of human primary thoracic spine mast cell sarcoma: a case reportAli C Ravanpay, Jonathan R Fromm, Kerstin L Edlefsen, et al.
Cytometry. Part B, Clinical Cytometry|August 6, 2014
Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemiaLorinda Soma, David Wu, Xueyan Chen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2014
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencingStephen J Salipante, Jonathan R Fromm, Jay Shendure, et al.
Cytometry. Part B, Clinical Cytometry|July 22, 2014
Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemiaLorinda Soma, David Wu, Xueyan Chen, et al.
Cytometry. Part B, Clinical Cytometry|September 7, 2016
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapySindhu Cherian, Valerie Miller, Vivian McCullouch, et al.
Cytometry. Part B, Clinical Cytometry|November 4, 2015
Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosisSindhu Cherian, Vivian McCullouch, Valerie Miller, et al.
Cytometry. Part B, Clinical Cytometry|April 25, 2015
Case study interpretation: Report from the ICCS Annual Meeting, Seattle, 2014Jonathan R Fromm, Damian J Tagliente, Aaron C Shaver, et al.
American Journal of Clinical Pathology|September 17, 2024
Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistryXueyan Chen, Lori Soma, Claire Murphy, et al.
Pageof 8